Literature DB >> 17297920

Zn(2+)-dependent misfolding of the p53 DNA binding domain.

James S Butler1, Stewart N Loh.   

Abstract

The DNA binding domain (DBD) of p53 folds by a complex mechanism that involves parallel pathways and multiple intermediates, both on- and off-pathway. This heterogeneity renders DBD particularly susceptible to misfolding and aggregation. The origins of parallel folding mechanisms are not well understood. DBD folding heterogeneity may be caused by the presence of the single bound Zn2+. To test that hypothesis, we carried out kinetic folding studies of DBD in its Zn2+-free form (apoDBD) and in the presence of various concentrations of free Zn2+ and the Zn2+-nitrilotriacetate (NTA) complex. Folding kinetics of apoDBD and DBD are similar, although apoDBD folds faster than DBD at some urea concentrations. The principle consequence of Zn2+ removal is to accelerate unfolding and simplify it from two exponential phases to one. Metal binding interactions are therefore not responsible for the observed complexity of the folding reaction. A slight stoichiometric excess of free Zn2+ arrests folding and traps the protein in a misfolded state in which Zn2+ is bound to nonphysiological ligands. Folding can be rescued by providing metal ions in the form of the NTA-Zn2+ complex, which simultaneously protects against misligation and provides a source of Zn2+ for regenerating the functional protein. This chemical metallochaperone strategy may be an effective means for improving folding efficiency of other metal binding proteins. The findings suggest that, in vivo, DBD must fold in an environment where free Zn2+ concentration is low and its bioavailability is carefully regulated by cellular metallochaperones.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297920     DOI: 10.1021/bi062106y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

2.  Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53.

Authors:  Xin Yu; Adam Blanden; Ashley T Tsang; Saif Zaman; Yue Liu; John Gilleran; Anthony F Bencivenga; S David Kimball; Stewart N Loh; Darren R Carpizo
Journal:  Mol Pharmacol       Date:  2017-03-20       Impact factor: 4.436

3.  Zinc deficiency causes neural tube defects through attenuation of p53 ubiquitylation.

Authors:  Huili Li; Jing Zhang; Lee Niswander
Journal:  Development       Date:  2018-12-13       Impact factor: 6.868

4.  Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore.

Authors:  Adam R Blanden; Xin Yu; Aaron J Wolfe; John A Gilleran; David J Augeri; Ryan S O'Dell; Eric C Olson; S David Kimball; Thomas J Emge; Liviu Movileanu; Darren R Carpizo; Stewart N Loh
Journal:  Mol Pharmacol       Date:  2015-02-20       Impact factor: 4.436

Review 5.  Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.

Authors:  Adam R Blanden; Xin Yu; Stewart N Loh; Arnold J Levine; Darren R Carpizo
Journal:  Drug Discov Today       Date:  2015-07-20       Impact factor: 7.851

Review 6.  A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.

Authors:  Jessica J Miller; Kalvin Kwan; Christian Gaiddon; Tim Storr
Journal:  J Biol Inorg Chem       Date:  2022-04-30       Impact factor: 3.862

7.  Aggregation of zinc-free p53 is inhibited by Hsp90 but not other chaperones.

Authors:  Huiwen Wu; H Jane Dyson
Journal:  Protein Sci       Date:  2019-09-30       Impact factor: 6.725

8.  MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy.

Authors:  A S Azmi; P A Philip; F W J Beck; Z Wang; S Banerjee; S Wang; D Yang; F H Sarkar; R M Mohammad
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

9.  Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism.

Authors:  Xin Yu; Adam R Blanden; Sumana Narayanan; Lalithapriya Jayakumar; David Lubin; David Augeri; S David Kimball; Stewart N Loh; Darren R Carpizo
Journal:  Oncotarget       Date:  2014-10-15

10.  Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions.

Authors:  Amir Eldar; Haim Rozenberg; Yael Diskin-Posner; Remo Rohs; Zippora Shakked
Journal:  Nucleic Acids Res       Date:  2013-07-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.